文献速递炎症性肠病

维得利珠单抗治疗非炎症性肠病相关肠病

Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-02-19

维得利珠单抗是α4β7整合素拮抗剂,已用于炎症性肠病治疗。其肠道选择性作用及良好安全性促使超说明书用于非IBD相关炎症性肠病,如显微镜性结肠炎、自身免疫性肠病和常见变异型免疫缺陷相关肠炎。本文通过文献综述评估维得利珠单抗治疗难治性非IBD肠病的临床、内镜和组织学改善。

要点

  • 维得利珠单抗通过阻断α4β7整合素与MAdCAM-1相互作用抑制肠道T细胞迁移。
  • 非IBD相关肠病缺乏获批疗法和既定治疗算法,治疗具有挑战性。
  • 综述评估维得利珠单抗对难治性非IBD肠病的临床、内镜和组织学改善。

核心结论

  • 维得利珠单抗可能用于治疗难治性非IBD相关肠病,但需文献综述评估其疗效。

研究设计与样本

  • 文献综述,评估维得利珠单抗治疗非IBD肠病(对常规治疗难治)的患者临床、内镜和组织学改善。

临床怎么用

  • 对于常规治疗难治的非IBD相关肠病,维得利珠单抗可作为超说明书治疗选择,但需进一步证据支持。

局限性

  • 非IBD相关肠病尚无获批疗法或既定治疗算法,综述基于有限文献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vedolizumab has become an integral part of the therapeutic armamentarium for patients with inflammatory bowel disease (IBD) who have failed conventional medical therapy. Vedolizumab is an α4β7 integrin antagonist that inhibits intestinal T-cell translocation by blocking integrin interactions with mucosal vascular addressin cellular adhesion molecule 1, reducing lymphocyte-mediated inflammation.1 Its gut selective mode of action and favorable safety profile have led to reports of off-label use for non-IBD-related inflammatory intestinal disorders, such as microscopic colitis,2 and small intestinal inflammatory conditions including autoimmune enteropathy3 and common variable immune deficiency-related enteritis.4 Treatment of non-IBD-related enteropathies is challenging with no approved therapies or established treatment algorithms. We conducted a literature review to assess clinical, endoscopic, and histologic improvement in patients treated with vedolizumab for non-IBD enteropathies refractory to conventional therapy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Akhtar HJ, Nguyen TM, Ma C, et al. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy. Clin Gastroenterol Hepatol. 2021. PMID: 33618025. doi:10.1016/j.cgh.2021.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。